Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for ...

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...

Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each. The ...

Haleon has gained full control of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake.

Pfizer sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the ...

Pfizer (NYSE:PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE:HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

(RTTNews) - Pfizer Inc. (PFE) announced the sales of around 618 million ordinary shares in Haleon plc (HLN) at a price of 385 pence or about $5.01 per Ordinary Share for gross proceeds of ...

Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

Per a previous share buyback plan, Pfizer sold around 44.14 million shares worth approximately $220 million (£170 million) directly to Haleon. Haleon was a consumer health joint venture (JV), an ...